we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.
Company profile
Ticker
BLUE
Exchange
Website
CEO
Nick Leschly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Genetix Pharmaceuticals Inc
SEC CIK
Corporate docs
Subsidiaries
bluebird bio Securities Corporation • bluebird bio France, SARL • bluebird bio (FR) SAS • bluebird bio Australia Pty Ltd • bluebird bio (Bermuda) Ltd • bluebird bio (UK) Ltd • bluebird bio (Italy) Srl • bluebird bio (Switzerland) GmbH • bluebird bio (Germany) GmbH • Bluebird Bio Greece Single Member, L.L.C. ...
BLUE stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
29 May 24
NT 10-Q
Notice of late quarterly filing
15 May 24
8-K
Results of Operations and Financial Condition
9 May 24
8-K
Entry into a Material Definitive Agreement
3 May 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Apr 24
8-K
Other Events
16 Apr 24
8-K
Results of Operations and Financial Condition
26 Mar 24
NT 10-K
Notice of late annual filing
26 Mar 24
8-K
Entry into a Material Definitive Agreement
18 Mar 24
8-K
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
8 Jan 24
Transcripts
BLUE
Earnings call transcript
2024 Q1
9 May 24
BLUE
Earnings call transcript
2023 Q4
26 Mar 24
BLUE
Earnings call transcript
2023 Q3
7 Nov 23
BLUE
Earnings call transcript
2023 Q2
8 Aug 23
BLUE
Earnings call transcript
2022 Q4
29 Mar 23
BLUE
Earnings call transcript
2021 Q2
9 Aug 21
BLUE
Earnings call transcript
2020 Q3
4 Nov 20
BLUE
Earnings call transcript
2020 Q1
11 May 20
BLUE
Earnings call transcript
2018 Q3
2 Nov 18
BLUE
Earnings call transcript
2017 Q3
1 Nov 17
Latest ownership filings
SC 13G/A
STATE STREET CORP
10 Apr 24
4
Richard A Colvin
5 Mar 24
4
Joseph Vittiglio
5 Mar 24
4
Andrew Obenshain
5 Mar 24
4
Christopher Krawtschuk
5 Mar 24
4
Thomas J Klima
5 Mar 24
SC 13G/A
PFM Health Sciences, LP
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
Alyeska Investment Group, L.P.
14 Feb 24
SC 13G
Granahan Investment Management, LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 218.37 mm | 218.37 mm | 218.37 mm | 218.37 mm | 218.37 mm | 218.37 mm |
Cash burn (monthly) | (no burn) | (no burn) | 28.24 mm | 9.70 mm | 20.62 mm | 23.12 mm |
Cash used (since last report) | n/a | n/a | 229.77 mm | 78.94 mm | 167.71 mm | 188.12 mm |
Cash remaining | n/a | n/a | -11.40 mm | 139.43 mm | 50.66 mm | 30.25 mm |
Runway (months of cash) | n/a | n/a | -0.4 | 14.4 | 2.5 | 1.3 |
Institutional ownership, Q1 2024
12.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 52 |
Opened positions | 10 |
Closed positions | 102 |
Increased positions | 15 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 5.44 bn |
Total shares | 13.50 mm |
Total puts | 806.90 k |
Total calls | 587.80 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
Growth Fund Of America | 5.20 mm | $515.44 mm |
Tang Capital Partners | 4.64 mm | $0.00 |
Susquehanna International | 1.33 mm | $1.71 bn |
BK Bank Of New York Mellon | 574.18 k | $734.95 mm |
Mirae Asset Global Investments | 325.11 k | $1.39 bn |
Simplex Trading | 260.55 k | $333.00 k |
Summit X | 229.77 k | $294.13 mm |
New York State Common Retirement Fund | 190.41 k | $244.00 k |
BNP Paribas Arbitrage | 102.10 k | $130.69 mm |
SG Americas Securities | 80.03 k | $102.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Andrew Obenshain | Common Stock | Sell | Dispose S | No | No | 1.5276 | 6,095 | 9.31 k | 279,998 |
4 Mar 24 | Thomas J Klima | Common Stock | Sell | Dispose S | No | No | 1.5276 | 4,573 | 6.99 k | 124,840 |
1 Mar 24 | Richard A Colvin | Common Stock | Sell | Dispose S | No | No | 1.5276 | 6,770 | 10.34 k | 118,368 |
1 Mar 24 | Richard A Colvin | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 199,000 | 310.44 k | 199,000 |
1 Mar 24 | Joseph Vittiglio | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 199,000 | 310.44 k | 199,000 |
1 Mar 24 | Andrew Obenshain | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 650,000 | 1.01 mm | 650,000 |
1 Mar 24 | Christopher Krawtschuk | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 199,000 | 310.44 k | 199,000 |
1 Mar 24 | Thomas J Klima | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 199,000 | 310.44 k | 199,000 |
News
bluebird bio Says Continuing To Work Expeditiously To Complete Delayed Filings
29 May 24
bluebird bio Names James Sterling As CFO, Effective June 10, 2024; Sterling Succeeds Chris Krawtschuk
29 May 24
10 Health Care Stocks With Whale Alerts In Today's Session
9 May 24
bluebird bio Q1 Sales $18.600M Miss $19.551M Estimate
9 May 24
Bluebird Bio Announces Receipt Of Expected Notice From Nasdaq; Company Has 60 Calendar Days From Receipt Of The Notice, Or Until June 24, 2024, To Submit A Plan To Regain Compliance With The Rule
26 Apr 24
Press releases
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
2 Jun 24
bluebird bio Appoints O. James Sterling as Chief Financial Officer
29 May 24
bluebird bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights – BLUE
28 May 24
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE
28 May 24
DEADLINE ALERT for BLUE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
28 May 24